Since<unk>  is cleared from the circulation through non-specific catabolism, no metabolic drug interactions are expected and no studies were done on routes of elimination. The systemic clearance rate is about 0.2 L/day and the terminal half-life is about 25 days.
Pembrolizumab
Nivolumab
Afatinib
Ipilimumab
Loncastuximab tesirine
Acalabrutinib
Imatinib
Sorafenib